ZORYVE foam is the first drug approved with a new mechanism of action for seborrheic dermatitis in over two decades.2 It’s bringing meaningful innovation to simplify disease management.1
ZORYVE foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE are flammable. Avoid fire, flame, and smoking during and immediately following application.
The most common adverse reactions (≥1%) include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).
Please see the full Prescribing Information for ZORYVE foam below.
ZORYVE foam is for topical use only and not for ophthalmic, oral, or intravaginal use.1
Our commitment to solving today’s biggest medical dermatology challenges doesn’t stop at bringing new treatment options. There’s more to our Arcutis DNA. It’s why we believe in responsible pricing and helping patients get access to our product through ZORYVE Direct and our commercial co-pay program, the ZORYVE Direct Savings Program, as well as Arcutis Cares.
ZORYVE Direct provides prescription status updates, refill reminders, and information to help patients stay on track with ZORYVE as prescribed by their healthcare provider. It also helps with out-of-pocket costs for eligible patients with commercial drug insurance.†
The Arcutis Cares patient assistance program (PAP) provides ZORYVE foam at no cost to eligible uninsured or underinsured patients with financial need.‡
†Subject to eligibility criteria and maximum program limitation. This offer is not valid for patients without commercial drug insurance or whose prescription claims are eligible to be reimbursed, in whole or in part, by any government program. Please see Terms and Conditions.
‡Subject to financial eligibility requirements. Other terms and restrictions apply.